So, Big Pharma--you all want to make a deal with biotech. But who's most likely to step up to the plate for Biogen Idec? Analysts put the price tag at $25 billion to $30 billion, so only the
Pfizer is crashing an online party for physicians. The drug maker has inked a deal with Sermo, a sort of Facebook for docs who want to gossip about their practices--drug side effects included.
According to a new report in Forbes, Pfizer went after Genentech wunderkind Susan Desmond-Heller to head up its new biomedical research operations. Desmond-Heller, who's had a head-turning run of
It's day three of the Pfizer-Sanofi merger watch. Sanofi-Aventis shares are up 5.5 percent on continued rumors of a Pfizer investment in its business. Now, experts are saying that a Sanofi
> Most women with breast cancer don't respond to the common chemo drug Taxol, according to a new study from the University of Texas M.D. Anderson Cancer Center--but the 15 percent to 20 percent
> Italy's Cosmo Pharmaceuticals will pick up a €2 million upfront fee after inking a global licensing deal with Ferring for a reformulated budesonide product. Cosmo also could receive up to
Say the Pfizer/Sanofi-Aventis rumors are true: Would merging with the French drug maker boost
> Visiomed Group and Clinical Cell Culture are merging into a $27 million biotech company.
Sanofi-Aventis stock spiked this morning after rumors of a Pfizer buyout sparked a flurry of trading. The oil company Total does own 13 percent of Sanofi, and it has been looking to offload those
It hasn't had a lot to show for it so far, but Pfizer became the world's number one spender on research and development last year, grabbing the top spot from Ford. The list, assembled by the